By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epistem today announced a research collaboration with GlaxoSmithKline to use its amplification technology to gain a better understanding of fibrosis.

The Manchester, UK-based firm will use its RNA-Amp technology to identify characteristics of diseased fibrotic tissue, Epistem said. The deal is for three years, but further terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.